Ginkgo Bioworks Holdings (DNA) Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Current Assets came in at $410.0 million in Q1 2026, down 27.38% YoY from $564.5 million in Q1 2025, and down 13.12% on a QoQ basis from $471.8 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Current Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Current Assets data on file, last reported at $410.0 million in Q1 2026.
- Quarterly Current Assets fell 27.38% year-over-year to $410.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $410.0 million (down 27.38% YoY) and the FY2025 annual result came in at $471.8 million, down 21.72% from the prior year.
- Current Assets eased to $410.0 million in Q1 2026, from $471.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.7 billion in Q1 2022 to a low of $410.0 million in Q1 2026.
- A 5-year average of $961.1 million and a median of $903.0 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 165261.75% — and 2024, when it plunged 41.98%.
- Tracing DNA's Current Assets over 5 years: stood at $1.5 billion in 2022, then tumbled by 30.92% to $1.0 billion in 2023, then sank by 39.83% to $602.7 million in 2024, then fell by 21.72% to $471.8 million in 2025, then decreased by 13.12% to $410.0 million in 2026.
- The last three Current Assets figures came in at $410.0 million (Q1 2026), $471.8 million (Q4 2025), and $506.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 332.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 332.54 Mn |
| Mar 31, 2026 | 409.96 Mn |
| Dec 31, 2025 | 471.84 Mn |
| Sep 30, 2025 | 506.08 Mn |
| Jun 30, 2025 | 523.03 Mn |
| Mar 31, 2025 | 564.53 Mn |
| Dec 31, 2024 | 602.74 Mn |
| Sep 30, 2024 | 662.48 Mn |
| Jun 30, 2024 | 783.36 Mn |
| Mar 31, 2024 | 903.02 Mn |
| Dec 31, 2023 | 1.00 Bn |
| Sep 30, 2023 | 1.14 Bn |
| Jun 30, 2023 | 1.22 Bn |
| Mar 31, 2023 | 1.33 Bn |
| Dec 31, 2022 | 1.45 Bn |
| Sep 30, 2022 | 1.46 Bn |
| Jun 30, 2022 | 1.60 Bn |
| Mar 31, 2022 | 1.71 Bn |
| Dec 31, 2021 | 1.72 Bn |
| Sep 30, 2021 | 1.81 Bn |